Clinical Trials
5
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Relapsed Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Opna Bio LLC
- Target Recruit Count
- 130
- Registration Number
- NCT06433947
- Locations
- 🇺🇸
Banner MD Anderson, Gilbert, Arizona, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
🇺🇸Emory Winchip Cancer Center, Atlanta, Georgia, United States
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: PLX2853 20 mgDrug: PLX2853 40 mgDrug: PLX2853 80 mg
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Opna Bio LLC
- Target Recruit Count
- 19
- Registration Number
- NCT04556617
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
- Conditions
- Gynecologic NeoplasmsEpithelial Ovarian Cancer
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Opna Bio LLC
- Target Recruit Count
- 37
- Registration Number
- NCT04493619
- Locations
- 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- Conditions
- Refractory Acute Myeloid Leukemia (AML)Relapsed Acute Myeloid Leukemia (AML)High-risk Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Opna Bio LLC
- Target Recruit Count
- 22
- Registration Number
- NCT03787498
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland, United States
🇺🇸NewYork-Presbyterian / Weill Cornell Medical Center, New York, New York, United States
A Study of PLX2853 in Advanced Malignancies.
- Conditions
- Small Cell Lung CancerUveal MelanomaOvarian Clear Cell CarcinomaNon-Hodgkin LymphomaAdvanced MalignanciesSolid TumorDiffuse Large B Cell LymphomaFollicular Lymphoma
- Interventions
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Opna Bio LLC
- Target Recruit Count
- 49
- Registration Number
- NCT03297424
- Locations
- 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸Sylvester Comprehensive Cancer Center / University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸Columbia University Medical Center, New York, New York, United States